Role of darunavir in the management of HIV infection by Lascar, R Monica & Benn, Paul
© 2009 Lascar and Benn, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
HIV/AIDS - Research and Palliative Care 2009:1 31–39
HIV/AIDS - Research and Palliative Care
31
R e V I e w
Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com
Dovepress 
Role of darunavir in the management  
of HIV infection
R Monica Lascar 
Paul Benn
The Mortimer Market Centre, 
Camden PCT, London wC1e 6JB
Correspondence: R Monica Lascar  
The Mortimer Market Centre, Camden 
PCT, London wC1e 6JB, UK 
Tel +44 20 75305055 
Fax +44 20 75305044 
email monix@doctors.net.uk
Abstract: There is an ongoing need for potent antiretroviral therapies to deal with the increasing 
pool of treatment-experienced patients with multiple drug resistance. The last few years have seen 
the arrival of 2 new and very potent protease inhibitors – darunavir and tipranavir – alongside 2 
whole new classes of anti-HIV agents – the integrase inhibitors and chemokine receptor CCR5 
antagonists. This review focuses on the role of darunavir in managing HIV infection, with 
an emphasis on darunavir’s exceptional resistance profile and related clinical effectiveness, 
pharmacokinetics, tolerability and toxicity data. Darunavir in combination with the pharmaco-
kinetic booster ritonavir has proved to be very effective in the treatment of highly treatment-
experienced HIV patients with multiple drug resistance. The favorable tolerability and toxicity 
profile alongside the drug’s high genetic barrier to the development of resistance prompted 
approval of darunavir for HIV-treatment naïve patients. Furthermore, the paradigm of treating 
HIV with a combination of anti-HIV agents is currently being challenged by ongoing darunavir 
monotherapy trials and these preliminary data will be discussed.
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Introduction
The definition of HIV treatment success in the era of highly active antiretroviral therapy 
(HAART) is a moving goalpost.
Alongside well-established measures of virological success as defined by an 
undetectable HIV load together with an increase in CD4 T-cell count1,2 there are other 
drivers of treatment success, which may influence patients’ and clinicians’ choices 
of antiretroviral regimens.
Safety and tolerability of antiretroviral drugs may be as important as potency in 
the case of treatment-naïve patients. For the increasing pool of treatment-experienced 
patients, the availability of new and potent antiretroviral agents with a high genetic 
barrier to the development of resistance is paramount. Given the crucial role of HIV 
protease in the HIV replication cycle, the protease inhibitor (PI) drugs remain one of 
the most valuable classes of anti-HIV drugs.
This review will focus on the new PI darunavir and its role it in the treatment of HIV .
Development of darunavir: pharmacology,  
mode of action, pharmacokinetics, drug interactions
Key steps leading to the development of TMC114 (darunavir)
The arrival of PIs in late 1996 had a major impact on reducing HIV-related morbidity 
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The work leading to the discovery of darunavir has 
been driven by several shortcomings that were evident with 
available antiretroviral regimes: the emergence of virologi-
cal failure in up to 50% of patients treated with conventional 
PI regimens4 and the increasing prevalence of primary 
transmission of drug-resistant HIV variants5–7 alongside 
toxicity and tolerability issues associated with the relatively 
high therapeutic doses required. New, more potent and 
better-tolerated PIs were urgently needed.
The HIV-1 protease remains a major target for the 
development of new anti-HIV-1 drugs. This highly specific 
non-promiscuous enzyme cleaves the post-translational 
precursor polyproteins Gag and Gag-Pro-Pol in at least 
9 sites, releasing 6 structural proteins (matrix, capsid, P2, 
nucleocapsid, P1 and P6) and 4 enzymes: protease, reverse 
transcriptase, RNAse and integrase. It is the essential role of 
protease in viral maturation8,9 that makes PIs such a crucial 
class of drugs for successful HIV treatment.
HIV PIs are a success of structure-based drug design.10 
Our knowledge of the structure, thermodynamics and 
dynamics of the active site within the protease enzyme has 
improved greatly in the last decade, allowing for the design of 
2 novel PIs – darunavir and tipranavir,11 both characterized by 
increased potency and higher genetic barrier to development 
of resistance.12
The key steps that took place in the development of 
darunavir, from lab bench to clinical practice, began in 
1998 when a first series of PIs with superior potency 
were initially described.13 New insights into the molecular 
interactions between the PI and the viral protease 
enzyme were highlighted by extensive X-ray studies of 
protein–ligand structures of wild type and mutant HIV 
proteases. The backbone binding concept hypothesis14–16 
has suggested that the active site backbone conformation 
of mutant proteases is only minimally altered. Therefore an 
inhibitor that maximizes interactions within the active site 
of HIV protease may also maintain such interactions in the 
presence of mutant proteases. In particular, structure-based 
drug design focused on increasing hydrogen-bonding 
interactions17,18 in the wild type enzyme, which would 
be difficult to overcome by mutant HIV strains, given 
that the enzyme backbone retains the same spatial 
conformation despite mutations. The way in which a drug 
fits within the substrate consensus volume, known as the 
substrate envelope, also influences drug’s resilience to 
the development of resistance. Detailed crystal structure 
analyses of the binding characteristics of the HIV protease 
complexes has supported this hypothesis.16,19,20
In addition, drug design also focused on increasing 
the oral bioavailability of the new PIs by replacing the 
previous peptide ligand with non-peptidic ones, and a fused 
bicyclic tetrahydrofuran (bis-THF) derivate was chosen. 
A similar bis-THF ligand has previously been used as part of 
amprenavir’s structure, resulting in improved bioavailability 
of this PI. This structural similarity between amprenavir 
and darunavir may be of clinical relevance in the context of 
development of cross-resistance between the 2 components, 
and these data will be discussed further.
Darunavir’s exceptional resistance profile was first 
demonstrated in vitro, where it outperformed other available 
PIs by a 6- to 13-fold difference in IC50 values.21,22 This 
superior potency was maintained against HIV-1 strains that 
were selected for saquinavir, amprenavir, indinavir, nelfinavir 
or ritonavir resistance, although somewhat lower activity was 
observed with amprenavir-resistant strains.21
Darunavir has been further developed through a unique 
research program, which assessed potential PI compounds 
against a large panel of recombinant HIV strains derived from 
highly PI-resistant clinical isolates.23 Following a selection 
process based on the drugs potency against both wild type 
and multi-drug resistant HIV strains alongside a favorable 
pharmacokinetic profile, darunavir was identified a the lead 
component for clinical development.24
Pharmacology
Darunavir’s affinity to the HIV-1 protease is defined by a 
dissociation constant Kd = 4.5 × 10–12M, which is 100 times 
higher than amprenavir and 1000 times higher than older PIs 
(indinavir, nelfinavir, ritonavir, saquinavir).25
Subsequent clinical studies26 have provided evidence on the 
high potency of darunavir when co-administered with low-dose 
ritonavir (100 mg) (DRV/r) both in highly PI-experienced 
patients as well as in treatment naïve, alongside a favorable 
tolerability and toxicity profile.
In vitro studies have demonstrated that darunavir is a 
highly potent PI, against both wild type and protease-resistant 
HIV strains, including a wide range of clinical isolates. This 
has been demonstrated with throughput cell-based screening 
assays, which permit assessment of wild type as well as 
PI-resistant HIV-1 viruses derived from clinical samples. 
The anti-HIV-1 in vitro activity of darunavir against wild 
type was demonstrated by a 50% effective concentration 
(EC50) of 1 to 5 nM and EC90 of 2.7 to 13 nM. Darunavir’s 
potency against resistant HIV-1 was assessed against an 
optimization panel containing 19 recombinant clinical 
isolates, which were known to have resistance to other PIs HIV/AIDS - Research and Palliative Care 2009:1 33
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(defined as a fold change in effective concentration – EC50 
of 4 nM/L). This demonstrated an EC50  10 nM in 18 out 
of 19 isolates, suggesting that darunavir would have activity 
against these resistant isolates. By comparison, assessing 
other PIs against the same panel of isolates resulted in EC50 
values of 100 nM in the majority of specimens (nelfinavir 
for 19 isolates, indinavir and ritonavir for 18, saquinavir for 
15 and lopinavir for 10).
Subsequently, darunavir’s potency was further assessed 
through drug sensitivity assays on a broad range of recent 
clinical isolates. Among the 1501 PI-resistant samples, of 
which 75% had an EC50  10 nM.23,27 Cross-resistance with 
other PIs in vitro was not observed, with the exception of 
amprenavir, where darunavir was less active against HIV-1 
strains selected for amprenavir resistance.23 This may be 
explained by the structure similarities between the 2 drugs.
An additional angle of studying a new drug’s genetic 
barrier to resistance is through the use of biosensor-based 
studies, also known as surface plasmon resonance technol-
ogy, which assesses the binding kinetics of the drug to the 
substrate.28 It is generally agreed that when resistance to PIs 
develops there is a decreased binding affinity, due to faster 
dissociation rate. In the case of darunavir a decrease of more 
than 1000 in binding affinity was required to see a decrease in 
antiviral effect, which is more than two orders of magnitude 
higher than observed for other PIs.
Pharmacokinetics
Dosage
Darunavir has been approved for treatment of HIV infection 
as part of highly active antiretroviral therapy in combination 
with other anti-HIV agents. Given the significantly increased 
bioavailability of darunavir when administered together with 
low dose ritonavir (100 mg), the use of unboosted darunavir 
is not recommended.
Darunavir is currently licensed to treat HIV-1 treatment 
experienced patients at a dosage of 600 mg together with 
ritonavir 100 mg twice daily (DRV/r 600/100 mg twice daily). 
The once daily administration of DRV/r (800/100 mg once 
daily) has been clinically evaluated as part of the proof of prin-
ciple trial (TMC114-C207) and POWER trials in treatment-
experienced patients as well as in treatment naïve patients 
as part of ARTEMIS trials. Pharmacokinetic studies suggest 
that in treatment-naïve patients DRV/r minimum plasma 
concentration levels remained below the predefined EC50 of 
55 mg/mL, which is in keeping with clinical efficacy results 
(84% HIV RNA  50 copies/mL at week 48.29 In the highly 
treatment experienced population part of POWER trials there 
was a trend towards a lower response rate to the once daily 
regimen versus the twice-daily administration (31% vs 47%, 
respectively). This suggests once-daily darunavir should be 
used with caution in highly treatment-experienced patients.
Absorption, distribution, metabolism, drug 
interactions and special populations
Orally administered DRV/r 600/100 mg twice daily is rapidly 
absorbed, reaching peak plasma concentrations within 2.5 to 
4 hours.30 The terminal elimination of darunavir is relatively 
long at 15 hours.
Darunavir is metabolized by the hepatic cytochrome 
P450, in particular CYP3A. Ritonavir acts as an inhibitor 
of CYP3A, therefore inhibiting the hepatic first pass of 
darunavir, an effect which is not enhanced by further 
increasing the ritonavir dose to more than 100 mg.31
Co-administration of darunavir with other drugs metabolized 
via the CYP3A pathway is contra-indicated. In the setting of 
HIV this includes certain cholesterol lowering agents such 
as simvastatin, antiarrhythmics (amiodarone, quinidine) 
and local anesthetic lidocaine. Co-administration with other 
inhibitors and/or inducers of CYP3A4 is not recommended, 
including antituberculous drugs rifampicin and other PIs, 
including lopinavir.
Darunavir is mainly protein bound (95%),32 and although 
no changes in total plasma darunavir concentration were 
reported in patients with mild or moderate liver disease, 
the concentration of unbound darunavir was increased in 
these groups. Manufacturers advise caution when using 
darunavir in patients with moderate liver disease and its use 
is contra-indicated in patients with severe liver disease.33. 
Co-infection with hepatitis B and C is not in itself a contra-
indication to using DRV/r, as reported by a substudy analysis 
of darunavir exposure in this group (POWER 3).34
With regards to darunavir’s penetration in other 
compartments such as the central nervous system (CNS), 
there are data suggesting good penetration in the CNS at 
levels sufficient to inhibit viral replication for wild-type 
virus.35 Few data are currently available on darunavir 
penetration in the genital tract.
Efficacy studies/clinical results
Clinical trial data on darunavir’s safety and efficacy stem from 
3 main trials: POWER trials on highly treatment-experienced 
patients; TITAN, which included less treatment-experienced 
patients who were lopinavir/ritonavir (LPV/r) naïve; 
and ARTEMIS trials with antiretroviral treatment-naïve 
patients.HIV/AIDS - Research and Palliative Care 2009:1 34
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Given the structure-based drug discovery and evaluation 
process21,23,27 which led to the identification of darunavir as 
a potent agent against multi-drug resistant HIV strains in 
vitro, the first logical step of clinical evaluation studies to 
be undertaken were in highly HIV treatment experienced 
patients.
Role of darunavir in treatment-
experienced patients
The POWER (Performance Of TMC114/ritonavir When 
evaluated in Treatment-Experienced patients with PI 
resistance) studies36 demonstrated DRV/r clinical safety and 
efficacy in patients with previous triple-class exposure and 
advanced HIV disease.
POWER1 and 2 studies were randomized, partially 
blinded, dose finding studies, which compared the efficacy of 
DRV/r against investigator-chosen control protease inhibitors 
(CPI) in addition to an optimized background therapy (OBT), 
in treatment-experienced patients with at least one primary 
PI mutation and HIV load 1000 copies/mL.
The use of enfuvirtide was permitted but tipranavir, 
another novel PI, was precluded as part of OBT. The 
clinician was only blinded to the dose of DRV/r used in the 
first 24 weeks (600/100 mg twice daily, 400/100 mg twice 
daily, 800/100 mg once daily and 400/100 mg once daily), 
which identified the DRV/r dose of 600/100 mg twice daily 
to achieve the best virological and immunological response. 
After this, patients receiving other doses of DRV/r were 
switched to 600/100 mg twice daily and patients receiving 
control PIs continued their regimens in the open label 
phase of the study. Results from POWER 1 and 2 studies 
over time are presented in Table 1. POWER 1, 2 and 3 
differed in geographical location, and inclusion of patients 
co-infected with hepatitis B and C (stable and without signs 
of chronic liver disease) was permitted in POWER 1 but not 
in POWER 2.
The primary end-point defined as drop in HIV viral load 
(VL) of at least 1 log10 copies/mL and assessed using the 
time to loss of virological response algorithm (TLOVR) 
was achieved by 61% (67/110) DRV/r patients compared 
to 15% (18/120) in the open label CPI arm after 48 weeks 
of treatment36 and this difference remained statistically 
significant through to week 9637 and week 14438 (P  0.001). 
This was an impressive result considering that the patients 
included in the POWER trials had fairly advanced disease as 
defined by a median HIV load of 4.61 log 10 copies/mL, a low 
mean CD4 count of 153 cells/mL and almost all the patients 
had used at least 2 PIs previously, with 63% appearing non-
sensitive to commercially available PIs at that time.
The higher the number of active anti-HIV agents used, 
the more likely that virological suppression of less than 
50 copies/mL was achieved. This was also confirmed in a 
subsequent study,39 which showed that although the risk of 
viral rebound in heavily pre-treated patients was higher in the 
first year, this decreased significantly the longer virological 
suppression was maintained. The best predictor of virological 
response was the fold change in EC50 values compared to 
wild-type reference virus.40
Table 1 Efficacy data for darunavir/ritonavir versus control PI regimens (POWER studies)36 and lopinavir/ritonavir (TITAN41) in treatment-
experienced patients
POWER 1
Virological response (24 wk) DRV/r 600/100 N = 60 CPI/r N = 60 P values
VL  400 67% 25% P = 0.001
VL  50 53% 18% P = 0.001
POWER 2
Virological response (24 wk) DRV/r 600/100 N = 39 CPI/r N = 42
VL  400 49% 10% P = 0.001
VL  50 39% 7% P = 0.001
TITAN
Virological response (48 wk) DRV/r (N = 298) LPV/r (N = 297)
VL  400 77% 67% P = 0.08
VL  50 71% 60% P = 0.05
Notes: Data suggest darunavir superiority as defined by HIV RNA  50 when compared to control PIs in the POweR trials and a trend towards superiority for LPV/r in TITAN 
at week 48 (clear superiority at week 96 – data not shown). The data illustrated here show virological responses to 600/100 twice daily darunavir ritonavir dosage only.
Abbreviations: CPI/r, protease inhibitor/ritonavir; DRV/r, darunavir/ritonavir; PI, protease inhibitor;   VL, viral load.HIV/AIDS - Research and Palliative Care 2009:1 35
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DRV/r was further evaluated in 595 PI-experienced 
patients who were naïve to LPV/r and were randomized 
to receive DRV/r or LPV/r as part of the TITAN trial 
(TMC114/ritonavir In Treatment-experienced pAtients 
Naïve to lopinavir). The primary end point was to prove 
non-inferiority of DRV/r (600/100 mg twice daily) vs LPV/r 
(400/100 mg twice daily) (VL  400 copies/mL at 48 weeks) 
and secondary endpoints included achieving a HIV VL of 
less than 50 copies/mL. Patients recruited were PI naïve in 
30% of the cases, 33% had used one PI in the past and the 
rest had been exposed to 2 PIs and the distribution of patients 
was well balanced between the 2 arms. Virological response 
at week 48 (Table 1) showed that 77% of DRV/r patients 
versus 68% of LPV/r achieved a HIV VL  400 copies/mL 
(estimated difference of 9%, 95% CI 2–16). This has dem-
onstrated that DRV/r was non-inferior to LPV/r and the 
secondary statistical analysis suggested superiority of DRV/r 
in this setting. Furthermore, patients recruited to the TITAN 
study had less advanced disease than in the POWER trials 
and use of enfuvirtide was not permitted. This suggests that 
the differences observed in the TITAN study were due to the 
intrinsic antiviral efficacy of DRV/r.
Further evidence on DRV/r efficacy comes from a 
single-center study of 109 three-class experienced patients 
who switched regimens to either (i) boosted darunavir, 
(ii) other PI or (iii) non-PI class (including raltegravir).42 
Multivariate analysis suggested that patients switching to 
darunavir or raltegravir or both were more likely to achieve 
the primary outcome of HIV RNA  50 copies/mL at 
24 weeks compared to those switching to another protease 
inhibitor (for darunavir 65%, odds ratio = 4.24 vs non-PI 
strategy). The results further confirm darunavir’s efficacy 
as shown by company-led trials (POWER and TITAN) 
and provide evidence on switching strategies for highly 
experienced patients.
Role of darunavir in treatment 
naïve patients
DRV/r at a once daily dose (800/100 mg once daily) was 
compared to LPV/r 800/200 mg total daily dose (15% of 
total patients received LPV/r once daily) in 689 treatment 
naïve patients with HIV RNA  5000 copies/mL as part 
of the ARTEMIS (AntiRetroviral Therapy with TMC114 
ExaMined In naïve Subjects) trial. All patients received a 
fixed dose combination of tenofovir disoproxil fumarate and 
emtricitabine.
The primary outcome measure was non-inferiority of 
DRV/r vs LPV/r as defined by achieving a HIV VL of less 
than 50 copies/mL in a TLOVR analysis at week 48. Overall 
response at 48 weeks showed 84% of subjects on DRV/r vs 
78% on LPV-R had a VL  50 copies/mL and DRV/r was 
non-inferior to LPV/r (P  0.005).43 In the superiority 
analysis at week 48 the estimated difference was 5.5% in 
favor of DRV/r, which was not statistically significant. 36% 
of patients in each arm had a HIV RNA  100,000 copies/mL 
at baseline and in this subgroup 79% of DRV/r vs 67% on 
LPV/r were undetectable at week 48 suggesting a statistical 
significant superiority of DRV/r in this high HIV load 
subgroup.
A more recent 96 weeks analysis44 confirmed non-
inferiority of DRV/r versus LPV-R in naïve patients, with a 
statistical difference of 8.4% and 95% confidence interval 
1.9 to 14.8 (P  0.001). In an intent-to-treat analysis 
DRV/r was shown to be superior to LPV/r at week 96 with 
regards to virological end point, which was achieved by 
79% of patients in DRV/r versus 65% treated with LPV/r 
(P = 0.012). However there were no significant differences 
in the median CD4 cell count increases from baseline within 
the 2 groups.
Darunavir monotherapy in patients 
with HIV RNA  50 copies/mL
Given the proven superiority of DRV/r when compared to 
CPIs in treatment experienced patients in the POWER and 
TITAN studies as well as in comparison to LPV/r in naïve 
patients (ARTEMIS), trials are currently underway to explore 
whether DRV/r monotherapy would be an effective way of 
managing HIV patients. The question being addressed is 
whether DRV/r monotherapy can be used as a maintenance 
therapy once the patient has achieved an undetectable viremia 
with a standard approved combination therapy. This would 
be a major shift in the paradigm of HIV care, where a return 
to an effective and tolerable anti-HIV monotherapy would 
potentially reduce unwanted side-effects for patients as well 
as costs for the care provider.
This hypothesis is currently being evaluated as part 
of 2 multicenter, open label randomized trials (MONET 
and MONOI), both recruiting patients who are stable on 
antiretroviral medication with an undetectable baseline HIV 
load, aiming to prove non-inferiority of DRV/r monotherapy 
versus standard HAART given as 2 nucleoside reverse 
transcriptase inhibitors (NRTI) together with DRV/r.45,46 
Results at 48 weeks showed that DRV/r monotherapy was 
non-inferior to 2 NRTI and DRV/r (MONET N = 123 
patients in each arm) in a per protocol analysis, with 86.5% 
remaining undetectable (HIV VL  50 copies/mL) in the HIV/AIDS - Research and Palliative Care 2009:1 36
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monoterapy arm versus 87.8% in the standard treatment 
arm (lower limit of the 95% CI at −10.1%). In the intent to 
treat analysis in MONOI45 (N = 225 divided in the 2 arms) 
non-inferiority could not be demonstrated, 87.5% in the 
monotherapy arm versus 91% of patients in the standard 
had undetectable viral load at week 48 (lower limit of 
the 95% confidence interval at −11% and less than the 
pre-established –10% threshold). The patients included 
in the MONOI study had more advanced disease and the 
identified trend towards non-inferiority (see Table 3), sug-
gests that longer term follow-up is required to delineate 
virological outcomes.
In those individuals experiencing low-level HIV 
virological rebound, no new darunavir-resistant mutations 
where detected and the reintroduction of 2 nucleoside 
analogues as part of HAART resulted in viral suppression 
below 50 copies/mL in all patients. Although these data are 
encouraging, longer follow-up is required to ensure that 
virological suppression is maintained in the longer term. 
There were no statistically significant differences in side 
effects in both groups at 48 weeks.
Furthermore, consideration to viral control in other 
compartments, such as CNS disease and genital tract is 
recommended before the use of PI monotherapy can be 
recommended.
Safety and tolerability
Boosted darunavir has been shown to be safe and well 
tolerated by treatment-experienced36 and treatment-naïve 
HIV patients. DRV/r was generally well tolerated by 
both groups of patients. Combined POWER analysis and 
TITAN data show that the main side effects reported in 
treatment experienced patients after 48 weeks of treat-
ment were similar to previous PIs and included diarrhea, 
nausea, headache, naso-pharyngitis and upper respiratory 
tract infections. Of note, the overall frequency of various 
side effects in the combined POWER analysis was higher 
in the CPI-treated patients, in spite of the lower levels of 
overall drug exposure in this group (where higher rates of 
treatment failure lead to more frequent treatment discon-
tinuation in the CPI group). Duration of treatment exposure 
was similar within the 2 arms of the TITAN study (53 vs 
51 weeks). No further tolerability issues became appar-
ent on subsequent follow-up for 144 weeks in POWER 
trials47 or up to week 96 follow-up from TITAN. Table 2 
illustrates frequency of adverse events in treatment-naïve 
and treatment-experienced patients.
Most common laboratory abnormalities were elevated 
lipids, which occurred at similar frequencies in both arms 
in treatment-experienced patients (incidence of trigliceride 
elevations was 5% or greater in both arms in POWER trials). 
In treatment-naïve patients in the ARTEMIS study the overall 
incidence of gastro-intestinal side effects was lower in the 
darunavir arm, a trend which continued to week 96 and was 
statistically significant (P  0.0001). The incidence of lipid 
abnormalities, both cholesterol and triglyceride elevations, 
was also lower in DRV/r-treated patients. Although there are 
no head-to-head comparisons between atazanavir, which has 
also been shown to have less impact on lipid profiles than 
other PIs and darunavir, a study in healthy volunteers found 
Table 2 Safety and tolerability summary data for darunavir/ritonavir in treatment-experienced and treatment-naïve patients
A.   TITAN safety and tolerability data in treatment experienced patients41
Grade 2–4 laboratory abnormalities 
(incidence  2%)
DRV/r (N = 298) LPV/r (N = 297)
Diarrhea 14 (4%) 34 (10%)*
Triglycerides increased 10 (3%) 38 (11%)
Total cholesterol increased 44 (13%) 78 (23%)
Low-density lipoprotein increased 44 (13%) 36 (11%)
B.   ARTEMIS safety and tolerability data in treatment-naïve patients29
Diarrhea 23 (7.7%) 43 (14.5%)*
Triglycerides increased 57 (19%) 75 (25%)*
Total cholesterol increased 94 (32%) 86 (29%)
Low-density lipoprotein increased 56 (19%) 50 (17%)
*P  0.05; *P  0.01.
Abbreviations: DRV/r, darunavir/ritonavir; LPV/r, lopinavir/ritonavir.HIV/AIDS - Research and Palliative Care 2009:1 37
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that both PIs had only minor and similar effects on lipid 
profile in the short term.48
None of the studies reported significant renal abnormalities 
with DRV/r and the incidence of rashes was greatest in the 
TITAN at 3%. Overall good tolerability is also reflected 
in the low discontinuation rates due to adverse events in 
the darunavir arm (3% at 48 weeks and 4% at 96 weeks in 
ARTEMIS trial).
Resistance to darunavir
Darunavir’s potency in vitro was demonstrated against wild 
type and multi-drug resistant clinical isolates.21,23 There was 
no cross-resistance with other PIs in vitro, although due to 
structural similarities with amprenavir this may potentially 
occur.21 Furthermore, in vitro selection studies suggested 
that resistance to DRV is slow to develop compared to 
existing PIs.23
The strongest predictor of virological response to 
darunavir in POWER trials was the fold change in EC50 
value for darunavir at baseline40 and 2 phenotypic clinical 
cut off (CCO) values were defined (low CCO = 10 and 
upper CCO = 40), which may aid clinicians with access to 
phenotypic information.
The number and type of mutations in the protease 
associated with increased fold change for darunavir were 
further analyzed at 24 weeks and subsequently in the 
POWER trials and 11 protease mutations associated with a 
decreased response to arunavir were identified: V11I, V32I, 
L33F, I47V , I50V , I54L/M, G73S, L76V , I84V and L89V , 
with 5 major resistance associated mutations (highlighted in 
bold) being more commonly observed and associated with 
treatment failure in highly treatment-experienced patients. 
Resistance to darunavir was more commonly observed when 
at least three darunavir resistance–associated mutations 
(RAMs) were present in the context of a high number (14) 
of baseline International AIDS Society resistance associated 
mutations IAS-USA PI RAMs.37,40
The prevalence of darunavir RAMs was analyzed in a 
retrospective study of 1021clinical isolates from a reference 
laboratory in Madrid. The genotypes of patients who had 
previously failed commercially available PIs were examined 
for the presence of DRV resistance-associated mutations 
and 3 or more were found in 6.7% of case but two-thirds of 
patients did not have any mutations detected.
Place in therapy
Undoubtedly, darunavir has secured a key place for use in 
patients with multi drug resistant HIV , where it was shown 
to be more potent than investigator selected PI in POWER 
and TITAN. Furthermore, an additional single center switch 
study further confirmed that three-class experienced patients 
switched to darunavir were more likely to achieve virological 
suppression than their counterparts switched to other PIs or 
to non-PI class.49 Use of DRV/r in treatment experienced 
patients is further backed up by cost effectiveness studies,50,51 
which evaluated treatment costs for HIV RNA reduction 
(0.5 log reduction) and CD4 count increases (25 cells rise) 
for boosted darunavir versus other antiretrovirals in treatment 
Table 3 Darunavir monotherapy data
A.  MONOI45
Virological response 
(48 wk)
DRV/r DRV/r + 2NRTI Difference  
(lower limit CI)
VL  50 PP (n = 204) 94.1% 99% −4.9 (−9)
VL  50 ITT (n = 225) 87.5% 92% −4.5 (−11)*
B.  MONET44
VL  50 PP 86.2% ( n = 123) 87.8% (n = 123) −1.6 (−10.1)
VL  50 ITT 84.3% (n = 127) 85.3% (n = 129) −1 (−9.9)*
*−11%  −10% (delta) failure to demonstrate non-inferiority in ITT analysis; *−9.9%  −12% (delta) showing non-inferiority of darunavir monotherapy in ITT analysis.
Notes: Both trials have recruited patients who are stable on antiretroviral medication with an undetectable baseline HIV load and were switched to receiving either ritonavir-
boosted darunavir monotherapy (DRV/r arm) versus triple therapy comprising ritonavir-boosted darunavir together with a fixed nucleoside backbone two nucleoside reverse 
transcriptase inhibitors (DRV/r + 2 NRTI arm).
A. Primary efficacy analysis results from MONOI study at week 48 (end point: HIV RNA  50 copies/mL) show non-inferiority of darunavir monotherapy in a per protocol 
(PP) analysis but not in the ITT analysis. Of note, the trial was powered to detect a difference ‘delta’ of –10%.
B. Primary efficacy results from MONET at week 48, with HIV RNA  50 copies/mL using a TLOVR algorithm (where switch equals failure) are shown. Darunavir monotherapy 
showed consistently non-inferior efficacy compared to triple therapy at week 48. Of note, the difference ‘delta’ was set at –12% in this trial.
Abbreviations: CI, confidence interval; DRV/r, darunavir/ritonavir; NRT, nucleoside reverse transcriptase inhibitors; PP, per protocol analysis; ITT, intent to treat analysis; 
VL, viral load.HIV/AIDS - Research and Palliative Care 2009:1 38
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experienced patients, using clinical data from POWER and 
TITAN trials. These studies showed that although costs var-
ied widely from US$132 for DRV/r to US$16,464 for T-20, 
the use of darunavir in this highly treatment-experienced 
population was cost-effective despite the higher initial pur-
chase price when compared to older PIs. This is due to the 
high efficacy of darunavir and secondary increase in CD4 
counts, which is associated with less HIV-related morbidity 
and associated health care costs.52
There are increasing data supporting the use of DRV/r in 
naïve patients, based on the drug’s favorable safety and toler-
ability profile, together with medium long-term efficacy data. 
It may be argued that the best strategy is to use highly potent 
anti-HIV therapy as first line in order to prevent treatment 
failure rather than keeping more potent agents as second line 
to deal with treatment failure when this occurs. The favorable 
toxicity and tolerability profile in treatment-naïve patients 
means darunavir is well placed for first-line treatment in those 
with treatment resistance. Studies evaluating the performance 
of darunavir with other classes of anti-HIV drugs and with 
existing agents such as efavirenz in treatment-naïve patients 
are required.
The accumulating data on the use of darunavir as mono-
therapy are encouraging and suggest that this strategy may 
be used as ‘maintenance’ therapy in patients with previous 
HIV RNA  50 copies/mL. However, further information is 
required on the durability of this strategy and implications for 
viral evolution in other compartments (CNS, genital tract).
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